Microbiome-Sparing Enzyme Inhibitors

About Symberix

Symberix is pioneering a novel class of microbiome-sparing therapeutics by developing small molecules that inhibit specific bacterial enzymes linked to disease, rather than killing bacteria outright. This strategy seeks to treat conditions like inflammatory diseases and mitigate antibiotic side effects without contributing to antimicrobial resistance or dysbiosis. The company is advancing a pipeline of preclinical candidates, leveraging its proprietary discovery platform to identify bacterial enzyme targets and design selective inhibitors. As a private, preclinical-stage biotech, Symberix represents a targeted investment in the next generation of microbiome modulation.

About Symberix

Symberix is pioneering a novel class of microbiome-sparing therapeutics by developing small molecules that inhibit specific bacterial enzymes linked to disease, rather than killing bacteria outright. This strategy seeks to treat conditions like inflammatory diseases and mitigate antibiotic side effects without contributing to antimicrobial resistance or dysbiosis. The company is advancing a pipeline of preclinical candidates, leveraging its proprietary discovery platform to identify bacterial enzyme targets and design selective inhibitors. As a private, preclinical-stage biotech, Symberix represents a targeted investment in the next generation of microbiome modulation.

Therapeutic Areas